TrialEuropean journal of neurology2020

Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.

T H Brannagan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.